{"product_id":"handbook-of-hypertension-isbn-9781405182508","title":"Handbook of Hypertension","description":"When treating hypertension, physicians now have a huge range of drugs from which to choose in formulating a management strategy. This accessible guide helps the busy clinician access specific information on available drugs as components of an integrated care plan.  \u003cp\u003eThe \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e is a comprehensive review of the evidence base for hypertension and associated disease, providing tables, figures, charts, and summaries of principal findings from clinical studies on hypertension – putting vital information within reach of the busy practitioner.\u003c\/p\u003e \u003cp\u003eContaining the most recent guidelines for global cardiovascular risk analysis and evidence-based reviews on important new advances and recent trials, consulting the \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e will save precious time and improve patient care.\u003c\/p\u003e  Provisional Table of Contents.  \u003cp\u003e\u003cb\u003eAbbreviations\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral Introduction\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIntroduction\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertension Syndrome.\u003c\/p\u003e \u003cp\u003eVascular Biology.\u003c\/p\u003e \u003cp\u003eFunctional Endothelium.\u003c\/p\u003e \u003cp\u003eEndothelial Dysfunction.\u003c\/p\u003e \u003cp\u003eNew Treatment Approach.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypothesis: Essential Hypertension and End-Organ Damage\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension Classification and Guidelines Wordwide\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertension in the US.\u003c\/p\u003e \u003cp\u003eJNC-7.\u003c\/p\u003e \u003cp\u003eNHANES III and IV.\u003c\/p\u003e \u003cp\u003eCHS.\u003c\/p\u003e \u003cp\u003eESH-ESC.\u003c\/p\u003e \u003cp\u003eISHIB.\u003c\/p\u003e \u003cp\u003eAHA.\u003c\/p\u003e \u003cp\u003eBHS\/NICE(RCP).\u003c\/p\u003e \u003cp\u003eJBS 2.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGlobal Cardiovascular Risk Calculation.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSecondary Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMeasurement of Blood Pressure\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eIndirect measurement of blood pressure.\u003c\/p\u003e \u003cp\u003eKorotkoff Sounds.\u003c\/p\u003e \u003cp\u003eCommon Mistakes in Blood Pressure Measurement.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension-Atherosclerotic Syndrome.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNormotensive Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePre-hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNonpharmacologic Treatment of Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eNutrition.\u003c\/p\u003e \u003cp\u003eNutraceuticals, Vitamins, Minerals and Antioxidants.\u003c\/p\u003e \u003cp\u003eDASH I and II Trials.\u003c\/p\u003e \u003cp\u003eSpecific Recommendations.\u003c\/p\u003e \u003cp\u003eObesity.\u003c\/p\u003e \u003cp\u003eExercise.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eApproaches to Selection of Antihypertensive Therapy\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eStepped Care.\u003c\/p\u003e \u003cp\u003eDemographics.\u003c\/p\u003e \u003cp\u003eSubsets of Hypertension.\u003c\/p\u003e \u003cp\u003eRenin Profiling: The Laragh Method.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHemodynamics in Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHemodynamics: Logical and Preferred Method to Reduce Blood Pressure.\u003c\/p\u003e \u003cp\u003eHemodynamic Effects of Antihypertensive Drugs.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension-Related End-Organ Damage.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLife Expectancy and Blood Pressure.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSystolic, Diastolic and Pulse Pressure Concepts.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIsolated Systolic Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eClinical Hypertension Trials and Antihypertensive\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDrug\u003c\/b\u003e \u003cb\u003eTherapy\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003eCompleted Trials and Trials in Progress.\u003c\/p\u003e \u003cp\u003eDiuretic and Beta-Blocker Trials.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials with Diuretics.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials with Beta-Blockers.\u003c\/p\u003e \u003cp\u003eMeta-Analysis of Various Clinical Trials.\u003c\/p\u003e \u003cp\u003eComparisons of ACE-Inhibitor therapy with Placebo.\u003c\/p\u003e \u003cp\u003eComparisons of Calcium-antagonist therapy with Placebo.\u003c\/p\u003e \u003cp\u003eComparisons of More Intensive Blood Pressure Lowering Strategies with Less.\u003c\/p\u003e \u003cp\u003eIntensive Strategies.\u003c\/p\u003e \u003cp\u003eComparisons of Ace-Inhibitor based Therapy with Diuretic-based or Beta-Blocker Therapy.\u003c\/p\u003e \u003cp\u003eComparisons of Calcium-antagonist-based Therapy with Diuretic or Beta-BlockerTherapy.\u003c\/p\u003e \u003cp\u003eComparisons of Ace-Inhibitor Therapy with Calcium-antagonist Therapy.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials in Hypertension and Clinical Outcomes.\u003c\/p\u003e \u003cp\u003eHealth Outcomes Meta-Analysis.\u003c\/p\u003e \u003cp\u003eComparing the CCBs to other Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eALLHAT Trial.\u003c\/p\u003e \u003cp\u003eALLHAT: Conclusions.\u003c\/p\u003e \u003cp\u003eASCOT Trial.\u003c\/p\u003e \u003cp\u003eSummary of Published Trials Involving CCBs.\u003c\/p\u003e \u003cp\u003eAngiotensin Converting Enzyme Inhibitors (ACEI) Trials.\u003c\/p\u003e \u003cp\u003eSummary of ACEI Trials.\u003c\/p\u003e \u003cp\u003eAngiotensin Receptor Blockers (ARBs) Trials.\u003c\/p\u003e \u003cp\u003eARBs Trials Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCoronary Heart Disease Risk Factor and Effects of Anti-hypertensive Drug Therapy\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eCoronary Heart Disease: Risk Factors.\u003c\/p\u003e \u003cp\u003eCoronary Heart Disease Risk Factors: More potential risk factors.\u003c\/p\u003e \u003cp\u003eInfluence of Diuretic and Beta-Blocker Therapy on CHD Risk Factors.\u003c\/p\u003e \u003cp\u003eAntihypertensive Drugs and Serum Lipids.\u003c\/p\u003e \u003cp\u003eSummary of Serum Lipids and Antihypertensive Therapy with Diuretics and.\u003c\/p\u003e \u003cp\u003eBeta Blockers.\u003c\/p\u003e \u003cp\u003eEffects of Antihypertensive Drugs on Coronary Heart Disease Risk Factors.\u003c\/p\u003e \u003cp\u003eAntihypertensive Drugs and Coronary Heart Disease Risk Factors: Summary.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers and Atherosclerosis (CHD Reduction Trials).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension and Renal Disease\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eClassification of Chronic Kidney Disease.\u003c\/p\u003e \u003cp\u003eHypertension and Renal Damage.\u003c\/p\u003e \u003cp\u003eHypertension-Related Renal Damage:.\u003c\/p\u003e \u003cp\u003ePostulated Mechanisms.\u003c\/p\u003e \u003cp\u003eIs Thiazide Diuretic-Based Antihypertensive Therapy Associated with Increased.\u003c\/p\u003e \u003cp\u003eRisk of Renal Injury.\u003c\/p\u003e \u003cp\u003eMajor Clinical Trials Showing Renoprotection.\u003c\/p\u003e \u003cp\u003eEffects of Antihypertensive Drugs on Renal Function.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension and Diabetes Mellitus\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertensive Diabetics: Mortality, Coronary Heart Disease and Antihypertensive.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eBP Level Effects on Type II-DM Nephropathy.\u003c\/p\u003e \u003cp\u003eRENAAL TRIAL.\u003c\/p\u003e \u003cp\u003eDiabetes Mellitus and Hypertension Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSelection of Therapy Based on Subsets of Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDemographics and Antihypertensive Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eResistant Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIsolated Systolic Hypertension in the Elderly.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertensive Urgencies and Emergencies.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTreatment; General Principles.\u003c\/p\u003e \u003cp\u003eTreatment; Choice of Drug.\u003c\/p\u003e \u003cp\u003eTreatment of Specific Hypertensive Disorders.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension in Pregnancy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral Review of Antihypertensive Drug Therapy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eQuality of Life and Antihypertensive Therapy (Selected Trials).\u003c\/p\u003e \u003cp\u003eAntihypertensive Drug Compliance.\u003c\/p\u003e \u003cp\u003eTotal Cost of Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eCharacteristics of the Ideal Antihypertensive Drug.\u003c\/p\u003e \u003cp\u003eCombination Antihypertensive Therapy: Selected Drugs.\u003c\/p\u003e \u003cp\u003eCombination Antihypertensive Therapy: Selected Drugs: Summary.\u003c\/p\u003e \u003cp\u003eAntihypertensive Therapy: Efficacy of Monotherapy.\u003c\/p\u003e \u003cp\u003eSelected Drug Interactions with Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eMaximum Recommended Doses of Antihypertensive Drugs with Best Treatment Characteristics.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSpecific Review of all Antihypertensive Drug Classes\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eDiuretics.\u003c\/p\u003e \u003cp\u003eDiuretics Highlights.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists: Similarities.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists: Highlights.\u003c\/p\u003e \u003cp\u003eComparison of Commonly Used Oral Central Alpha-Agonists.\u003c\/p\u003e \u003cp\u003ePostganglionic Neuron Inhibitors.\u003c\/p\u003e \u003cp\u003ePostganglionic Neuron Inhibitors Highlights.\u003c\/p\u003e \u003cp\u003eBeta-Blockers—General.\u003c\/p\u003e \u003cp\u003eSide Effects and Contraindications of Beta-Blockers.\u003c\/p\u003e \u003cp\u003eDrug Interactions with Beta-Blockers.\u003c\/p\u003e \u003cp\u003eBeta-Blockers Highlights.\u003c\/p\u003e \u003cp\u003eDirect Vasodilators.\u003c\/p\u003e \u003cp\u003eDirect Vasodilators Highlights.\u003c\/p\u003e \u003cp\u003eAlpha1-Blockers.\u003c\/p\u003e \u003cp\u003eAlpha1-Blockers: Highlights.\u003c\/p\u003e \u003cp\u003eAngiotensin-Converting Enzyme (ACE) Inhibitors.\u003c\/p\u003e \u003cp\u003eRenin-Angiotensin System (RAAS).\u003c\/p\u003e \u003cp\u003eACE Inhibitors: Highlights.\u003c\/p\u003e \u003cp\u003eNon Hypertensive Treatment Effects of ACEIs.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers: Highlights.\u003c\/p\u003e \u003cp\u003eTreatment: Non Hypertensive Effects of CCBs.\u003c\/p\u003e \u003cp\u003eAngiotensin II Receptor Blockers (ARBs).\u003c\/p\u003e \u003cp\u003eAng-II Receptor Blockers (ARBs): Highlights.\u003c\/p\u003e \u003cp\u003eNon Hypertensive Treatment effects of ARB’s.\u003c\/p\u003e \u003cp\u003eRenin Inhibitors.\u003c\/p\u003e \u003cp\u003eSerum Aldosterone Receptor Antagonists (SARA’s).\u003c\/p\u003e \u003cp\u003eCombination of Anti-hypertensive Drug with Statin ( Amlodipine with Atorvastatin).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eArterial Compliance: Structure\/Function: Treatment.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSelected Combination Antihypertensive Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension Drug Selection: Summary.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNew Antihypertensive Drug Classes.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSubset Selection of Antihypertensive Therapy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eConclusions 383.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eReferences 385.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex 400.\u003c\/b\u003e\u003c\/p\u003e  \u003cb\u003eMark C. Houston\u003c\/b\u003e, MD, MSc, FACP, FAHA\u003cbr\u003e Associate Clinical Professor of Medicine\u003cbr\u003e Vanderbilt University School of Medicine\u003cbr\u003e ASH Specialist in Clinical Hypertension\u003cbr\u003e Director, Hypertension Institute and Vascular Biology, Nashville, Tennessee\u003cbr\u003e Section Chief, Division of Nutrition and Clinical Research\u003cbr\u003e Staff Physician, Vascular Institute\u003cbr\u003e Saint Thomas Hospital\u003cbr\u003e Nashville, Tennessee  When treating hypertension, physicians now have a huge range of drugs from which to choose in formulating a management strategy. This accessible guide helps the busy clinician access specific information on available drugs as components of an integrated care plan.  \u003cp\u003eThe \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e is a comprehensive review of the evidence base for hypertension and associated disease, providing tables, figures, charts, and summaries of principal findings from clinical studies on hypertension – putting vital information within reach of the busy practitioner.\u003c\/p\u003e \u003cp\u003eContaining the most recent guidelines for global cardiovascular risk analysis and evidence-based reviews on important new advances and recent trials, consulting the \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e will save precious time and improve patient care.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989334802661,"sku":"NP9781405182508","price":136.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405182508.jpg?v=1761783709","url":"https:\/\/k12savings.com\/es\/products\/handbook-of-hypertension-isbn-9781405182508","provider":"K12savings","version":"1.0","type":"link"}